Receptor-interacting protein 1 kinase inhibition therapeutically ameliorates experimental T cell-dependent colitis in mice
Open Access
- 6 April 2020
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Cell Death & Disease
- Vol. 11 (4), 1-4
- https://doi.org/10.1038/s41419-020-2423-2
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory DiseasesJournal of Medicinal Chemistry, 2017
- NEMO Prevents RIP Kinase 1-Mediated Epithelial Cell Death and Chronic Intestinal Inflammation by NF-κB-Dependent and -Independent FunctionsImmunity, 2016
- Characterization of GSK′963: a structurally distinct, potent and selective inhibitor of RIP1 kinaseCell Death Discovery, 2015
- A20 Restricts Ubiquitination of Pro-Interleukin-1β Protein Complexes and Suppresses NLRP3 Inflammasome ActivityImmunity, 2015
- Cutting Edge: RIP1 Kinase Activity Is Dispensable for Normal Development but Is a Key Regulator of Inflammation in SHARPIN-Deficient MiceThe Journal of Immunology, 2014
- Necroptosis Is Active in Children With Inflammatory Bowel Disease and Contributes to Heighten Intestinal InflammationAmerican Journal Of Gastroenterology, 2014
- Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiencyNature Immunology, 2012
- Successful Treatment with Infliximab for Inflammatory Colitis in a Patient with X-linked Anhidrotic Ectodermal Dysplasia with ImmunodeficiencyJournal of Clinical Immunology, 2011
- Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitisNature, 2011
- Necroptosis as an alternative form of programmed cell deathCurrent Opinion in Cell Biology, 2010